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Background: In PEPCAD-DES late loss as well as the need for repeat revascularization
was significantly reduced with drug coated balloon (DCB) angioplasty compared with
plain old balloon angioplasty (POBA) for drug-eluting stent (DES) restenosis (clinical
trials.gov NCT00998439). We now evaluated whether the use of DCB is different in
paclitaxel DES restenosis or non-paclitaxel DES restenosis.
Methods: 110 patients with a DES restenosis of either Sirolimus- (SES), Everolimus-
(EES) or Paclitaxel-eluting (PES) stents in a native coronary artery with indication for
percutaneous coronary intervention with a reference diameter ranging from 2.5mm to 3.5
mm and lesion length less or equal to 22 mm were randomized to treatment with either
DCB or POBA in six centers. 38 patients were randomized to POBA and 72 patients to
DCB. Patients suffered from repeat restenotic lesion (2nd) in 55.6% (N50) in DCB
group and 52.6% (N20) in POBA population. In the DCB group restenosis was located
in SES (N41, 56.9%), PES (N20, 27.7%) or EES (N11, 15.3%). Numbers for
POBA group were SES (N27, 71.1%), PES (N7, 18.4%) or EES (N3, 13.2%).
Results: DCB as compared with POBA significantly reduced late loss in PES restenosis
and non-PES restenosis with 0.460.50mm vs. 1.581.03mm (p0.002) and
0.310.54mm vs. 0.900.67mm (p0.001), respectively. Furthermore, TLR rates were
lower with DCB versus POBA for PES restenosis (5% vs. 57.1%, p0.001) and non-PES
restenosis (18.5% vs. 32.3%, p0.002). Late loss did not differ for PES versus SES
lesions with DCB treatment (0.46 vs. 0.31mm, p0.123). DCB was superior to POBA for
treatment of a first restenosis and forsecond restenosis with a late loss of 0.350.60mm
vs. 0.650.60mm (p0.128) and 0.490.61mm vs. 1.340.76mm (p0.001), respec-
tively.
Conclusions: Paclitaxel coated balloon angioplasty was superior to POBA for treatment
of PES and non-PES restenosis. DCB effect on late loss did not differ between type of
DES.
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Background: Drug-eluting stents constitute a major achievement in preventing resteno-
sis, concerns remain regarding the increased inflammatory and thrombogenic responses
associated with the polymers used. This analysis focuses on outcomes in patients
receiving the polymer-free microporous rapamycin-eluting stent system YUKON-Choice
(Yukon-DES, Translumina, Hechingen, Germany).
Methods: From 01/2006-09/2008 all consecutive patients (pts) receiving Yukon-DES
(2,5mm diameter) were prospectively enrolled in our registry. 6-months angiographic
and long-term clinical outcomes were analysed. The primary endpoint was cumulative
long-term major adverse cardiac events (MACE).
Results: 701 pts with 724 lesions (1050 stents) were included in our registry. Mean age
was 65.710 years (73% male). Risk factors included hypercholesterolemia (57.6%),
hypertension (74.8%), and diabetes (35.5%); table 1. Indication for percutaneous coronary
intervention was acute coronary syndrome in 32.2%. 76% of the lesions were of Type
B2/C, target vessel was left anterior descending artery in 35.2%, and 23.2% were chronic
total occlusions. Lesion length was 24.65.2 mm and mean stent diameter was 2.80.4
mm; table 1. A total of 511 pts (72%) underwent 6-months angiographic follow-up, binary
restenosis was noted in 23.5%. At 5 years clinical outcomes of 625/701 (89%) followed
patients were: cardiac death 5.8%; myocardial infarction 3.4%; and target vessel
revascularisation 24.6%. The cumulative five-year incidence of MACE was 35.4% (6.7%
per year). Incidence of stent thrombosis (ST) was 2.86% (30/1050) [definite 0.86%;
probable 0.29%; possible 1.8%]. Incidence of very late (1 year) definite/possible ST was
0.29%)].
Baseline characteristics
Age (years) 65.7 10
Male 512 (73.0%)
History of PCI 372/701 (53.1%)
History of CABG 130/701 (18.5%)
History of MI 401/701 (57.2%)
Clinical presentation
Acute coronary syndrome 226/701 (32.2%)
Stable angina/silent ischemia 475/701 (67.8%)
Current smoker 149/701 (21.3%)
Hypertension 524/701 (74.8%)
Diabetes 249/701 (35.5%)
Insulin treated 89/701 (12.7%)
Hypercholesterolemia 404/701 (57.6%)
Renal insufficiency 67/701 (9.6%)




Lesion length 24 mm 171 (23.6%)
ACC/AHA lesion type B2/C 555 (76.6%)
Lesion in bypass graft 72 (9.9%)
Pre-index procedure ISR 109 (15.1%)
Total occlusion 168 (23.2%)
Left main artery lesion 11 (1.5%)
Left anterior descending artery lesion 255 (35.2%)
Right coronary artery lesion 231 (31.9%)
Left circumflex lesion 227 (31.2%)
Bifurcation lesion 53 (7.3%)
Multiple study stents 253 (34.9%)
Predilatation performed 277 (26.4%)
Postdilatation performed 105 (10%)
Maximum postdilatation pressure (atm)
Mean 15.3 5.1
Range 8 – 25
Maximum stent deployment pressure
(atm)
Mean 15.6 1.7
Range 8 – 24
Mean stent diameter (mm) 2.8 0,4 mm
Total study stent length (mm) 24.6 5.2
Conclusions: Our registry data suggests that the implantation of YUKON-DES is feasible
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Background: Proximal coronary artery disease is associated with a poorer prognosis
compared to disease in the distal coronary arteries. PCI of a culprit lesion in the left
anterior descending artery (LAD) may have a worse prognosis than PCI of the proximal
left circumflex (LCX) or right coronary arteries (RCA). The possible disparity in risk may
be attenuated by stenting strategy. The aim of the present study was to evaluate outcome
after PCI of solitary proximal stenoses of the LAD as compared to the LCX and the RCA.
Methods: We used data from the Swedish angiography and angioplasty registry
(SCAAR), a national registry including all patients undergoing percutaneous coronary
intervention (PCI) in Sweden. From 2005 to 2011 all cases of proximal one- vessel
disease, treated with PCI, were identified. The patients were stratified according to culprit
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